# Coherus Oncology, Inc. (CHRS) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Coherus Oncology, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/CHRS/mda/fy2025/): filed 2026-03-09; accession 0001104659-26-025308 (https://www.sec.gov/Archives/edgar/data/1512762/000110465926025308/chrs-20251231x10k.htm); latest 10-K
- [FY 2024 MD&A](/company/CHRS/mda/fy2024/): filed 2025-03-17; accession 0001558370-25-003126 (https://www.sec.gov/Archives/edgar/data/1512762/000155837025003126/chrs-20241231x10k.htm)
- [FY 2023 MD&A](/company/CHRS/mda/fy2023/): filed 2024-03-15; accession 0001558370-24-003436 (https://www.sec.gov/Archives/edgar/data/1512762/000155837024003436/chrs-20231231x10k.htm)
- [FY 2022 MD&A](/company/CHRS/mda/fy2022/): filed 2023-03-06; accession 0001558370-23-002917 (https://www.sec.gov/Archives/edgar/data/1512762/000155837023002917/chrs-20221231x10k.htm)
- [FY 2021 MD&A](/company/CHRS/mda/fy2021/): filed 2022-02-23; accession 0001558370-22-001764 (https://www.sec.gov/Archives/edgar/data/1512762/000155837022001764/chrs-20211231x10k.htm)

Back to /company/CHRS/